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Abstract
Background: Mitigating or reducing the risk of medication harm is a global policy priority. But evidence reflecting
preventable medication harm in medical care and the factors that derive this harm remain unknown. Therefore, we
aimed to quantify the prevalence, severity and type of preventable medication harm across medical care settings.
Methods: We performed a systematic review and meta-analysis of observational studies to compare the prevalence
of preventable medication harm. Searches were carried out in Medline, Cochrane library, CINAHL, Embase and
PsycINFO from 2000 to 27 January 2020. Data extraction and critical appraisal was undertaken by two independent
reviewers. Random-effects meta-analysis was employed followed by univariable and multivariable meta-regression.
Heterogeneity was quantified using the I2 statistic, and publication bias was evaluated. PROSPERO:
CRD42020164156.
Results: Of the 7780 articles, 81 studies involving 285,687 patients were included. The pooled prevalence for preventable
medication harm was 3% (95% confidence interval (CI) 2 to 4%, I2 = 99%) and for overall medication harm was 9% (95%
CI 7 to 11%, I2 = 99.5%) of all patient incidence records. The highest rates of preventable medication harm were seen in
elderly patient care settings (11%, 95% 7 to 15%, n= 7), intensive care (7%, 4 to 12%, n = 6), highly specialised or surgical
care (6%, 3 to 11%, n = 13) and emergency medicine (5%, 2 to 12%, n = 12). The proportion of mild preventable
medication harm was 39% (28 to 51%, n = 20, I2 = 96.4%), moderate preventable harm 40% (31 to 49%, n = 22, I2 = 93.6%)
and clinically severe or life-threatening preventable harm 26% (15 to 37%, n = 28, I2 = 97%). The source of the highest
prevalence rates of preventable harm were at the prescribing (58%, 42 to 73%, n = 9, I2 = 94%) and monitoring (47%, 21
to 73%, n = 8, I2 = 99%) stages of medication use. Preventable harm was greatest in medicines affecting the ‘central
nervous system’ and ‘cardiovascular system’.
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Conclusions: This is the largest meta-analysis to assess preventable medication harm. We conclude that around one in
30 patients are exposed to preventable medication harm in medical care, and more than a quarter of this harm is
considered severe or life-threatening. Our results support the World Health Organisation’s push for the detection and
mitigation of medication-related harm as being a top priority, whilst highlighting other key potential targets for remedial
intervention that should be a priority focus for future research.
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Background
The Institute of Medicine report ‘To Err is Human: Build-
ing a Safer health System’ helped generate the patient
safety movement by reporting that up to 98,000 deaths
were due to medication and at least some of them could
have been preventable [1–3]. On March 2017, the World
Health Organisation (WHO) launched a global initiative
to develop approaches to reduce severe, preventable medi-
cation harm in all countries by 50% over the next 5 years
[4]. Similarly, in May 2018, the Institute for Healthcare
Improvement of the USA launched a multi-organisation
initiative to create a national action plan for the preven-
tion of harm in healthcare [5].
In the USA alone, medication errors are the third most
common cause of death behind heart disease and cancer
[6] accounting for injuries to approximately 1.3 million
people annually [7, 8]. Similarly, in the UK, it was esti-
mated that there are 237 million medication errors in
England over a year period [9, 10], and preventable ad-
verse drug reactions were estimated to cost the National
Health Service (NHS) £98.5 million per annum, con-
sume 181,626 bed days, cause 712 deaths and contribute
to 1708 deaths during initial hospitalisation.
It is important to underline that not all harms caused
by medication errors are preventable. However, distinc-
tion between preventable and non-preventable harm is
becoming increasingly important, because it provides an
indication of where best to invest limited resources for
healthcare improvement in order to have the greatest
benefit. From a quality improvement perspective, meas-
uring harm, particularly preventable harm, alongside
medication error [11] is critical. This would help ensure
efforts are more patient-centred; can target the system
rather than the individual, with the aim of enhancing
clinical outcomes; reduce punitive concerns associated
with the reporting methodology; allow for analysis of un-
intended results and encourage learning from events to
continually improve the processes for detecting prevent-
able harm [12]. Practitioners should also supplement
preventable medication harm assessment with the meas-
urement of certain contributory factors such as the se-
verity of harm, the source at which the harm occurred
(i.e. prescribing, transcribing, dispensing, administering
or monitoring) and classification of harm according to
the ‘five rights’ (patient, drug, dose, route, and time).
Each of these factors could significantly inform quality
improvement efforts [13].
Due to the ongoing global challenges in this area, it is
important that healthcare providers, researchers and pol-
icy makers have a better understanding about the
current prevalence rates and nature of preventable medi-
cation harm. Therefore, we undertook a systematic re-
view and meta-analysis to inform the identification of
targets for improvement efforts on estimating the preva-
lence of preventable medication harm across medical
care settings including hospitals, primary care and vari-
ous specialties. We also examined the clinical severity of
preventable medication harm, and the impact of the
medication use, stage and high-risk medication groups
by building on what is already known from previous re-
search efforts [14–16].
Methods
This systematic review was conducted and reported in
accordance with the Reporting Checklist for Meta-
analyses of Observational Studies (MOOSE). The com-
pleted MOOSE checklist is available in Additional file 1:
Table S1. The review protocol is registered in PROS-
PERO under the review number: CRD42020164156.
Data sources and searches
We searched the five electronic bibliographic databases
from 2000 to 27 January 2020: Medline, Cochrane li-
brary, Embase and PsycINFO via Ovid and CINAHL via
EBSCO. The searches were supplemented by checking
conference abstracts and screening grey literature
sources (WHOLIS, Google Scholar, SIGLE). We also
identified eligible studies by checking references in exist-
ing systematic reviews in the area. The full search strat-
egy is available in the Additional file 2: Table S2.
Eligibility criteria
We included observational studies (retrospective and
prospective cohorts; cross-sectional studies) in any med-
ical care setting (primary, secondary and tertiary care)
published from January 2000 onwards in English lan-
guage. This date was selected, because it coincides with
the publication of landmark patient safety reports, the
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increase of patient safety research in volume and the as-
sessment of preventability [1, 17, 18]. The primary out-
come was the prevalence of preventable medication-
related harm including [19] adverse drug events (ADEs)
or adverse drug reactions (ADRs) whether they were acts
of omission or commission, incorrect medication/dose/
timing, administration of a medication to a patient with
a known allergy, inadequate monitoring or other errors.
For inclusion in this study, the study authors clearly de-
fined their inclusion criteria as being about ADEs or
ADRs and assessment of preventability. We only in-
cluded studies that provide amenable data for inclusion
in meta-analysis. Studies reporting medication errors or
non-adherence and that involved only patients with re-
admissions due to recurring medication harm were
excluded.
Study selection and data extraction
The titles and abstracts of all identified citations as well
as potentially eligible full texts were screened independ-
ently by two reviewers (AH, MP), using pre-defined cri-
teria. Disagreements were settled through consultation
with a third team member (RNK). For eligible studies,
we used a pilot-tested extraction spreadsheet, to extract
descriptive data on study characteristics (e.g. number
and age of participants, research design, systems used
for data collection, assessment and preventability) and
quantitative outcomes (prevalence, severity, medical care
setting, the medication group and stage of medication
use of preventable medication harm). Two independent
researchers (AH and NT) performed the data extraction
with disagreements resolved by discussion within the
wider team (MP, RNK, DMA).
Risk of bias assessment
The quality of the studies was evaluated by two inde-
pendent reviewers (AH and NT) using the Newcastle-
Ottawa scale for cross-sectional and cohort studies. This
assessed the representativeness of the sample size, re-
sponse rate, ascertainment of the exposure, control of
confounding variables, assessment of preventability and
timing and appropriate statistical analysis, which pro-
vided a score ranging from 0 (lowest grade) to 10 (high-
est grade). A higher grade indicated a lower risk of bias.
For our analyses, studies scoring 7 or above were consid-
ered as low risk, whereas studies scoring below 7 were
considered as high risk of bias.
Data analysis
Prevalence of preventable medication harm was pooled
using random-effects models with the DerSimonian-Laird
approach [20]. Secondary analysis looked at WHO priority
areas including the healthcare system setting (i.e. general
hospital/internal medicine; emergency department or
ICU; highly specialised or surgical care—which included
hospitals with long-term acute care facilities for dealing
with certain disease categories such as cardiac, oncology,
or orthopaedic problems; care units for paediatric patients,
including neonatal intensive care units; and elderly pa-
tients, including geriatric patients aged above 64 years),
the severity (i.e. mild, moderate, severe/life-threatening),
stage of medication (i.e. using the US Pharmacopeia five
major steps [21]: prescribing, transcribing and document-
ing, dispensing, administering and monitoring), patient
age distribution (new born (less than 3 years), adolescents
(3 to 18 years), adults (19 to 69 years), elder (70 years or
above)) based on mean or median and medication group
according to the Anatomical Therapeutic Chemical
(ATC) Classification System [22].
Unadjusted prevalence, incidence and standard errors
for the study-specific estimates were recalculated, based
on the information of crude numerators and denomina-
tors provided in the individual studies. To keep the ef-
fect of studies with extremely small prevalence estimates
on the overall estimate to a minimum, the variance of
the study-specific prevalence was stabilised with the
Freeman-Tukey double arcsine transformation [23]. Sen-
sitivity analyses were done using other transformations,
a range of sample sizes and adjustments for between-
study variance (τ2) [24–27].
Univariable and multivariable meta-regressions were
performed to investigate possible sources of heterogen-
eity using the following variables: WHO region (North
America, Europe and Asia), drug class, median sample
size, age group (adolescent, adults or mixed), medical
setting (same as healthcare system setting), assessment
method (medical record review or survey/telephone/vol-
untary report), standard preventability assessment
method (i.e. Hallas criteria [28] or Schumock and
Thornton scale [29]) and severity classification system,
length of study (less than 6 months or more), design
(prospective cohorts, retrospect cohorts or cross-
sectional) and sensitivity analysis with studies at lower
risk of bias.
Heterogeneity was assessed using the χ2 test on
Cochrane’s Q statistic and quantified by calculating I2
[30]. Values of 25%, 50% and 75% for I2 represent low,
medium and high heterogeneity [31]. The presence of
publication bias was assessed by inspection of funnel
plots, the Egger’s test and the trim-and-fill method. All
analyses were done using the ‘meta’ and ‘metafor’ pack-
ages of the statistical software R (v.3.6.3) [32]; specific-
ally, the ‘metaprop’ function was used for pooling
prevalence rates.
Patient and public involvement
Six patients who were members of our research advisory
panel were involved in the development of our research
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questions, research protocol and selection of outcomes
and they advised on the interpretation and dissemination
of results.
Results
The searches revealed 7868 articles, and after reviewing
the full text screening, 81 studies met the inclusion cri-
teria (see PRISMA flow chart in Fig. 1). A list of the eli-
gible studies is included in Additional file 3: Table S3.
Characteristics of included studies
Twenty-six of the studies (32%) were conducted in Eur-
ope, 23 studies (28%) in the USA, and the rest of the
studies were mainly carried out in South East Asia,
South America or the Middle East. The median sample
size across studies was 1234 patients (IQR estimate
2652). The pooled sample size across the 81 eligible
studies was 285,687 patients. Of these, 18,243 (6.4%) pa-
tients experienced at least one classified medication re-
lated harm, and 7075 (2.5%) experienced at least one
preventable medication harm. In total, 20,698 medica-
tion harm incidents were reported, of which 7589 (37%)
were preventable medication harm.
Fifty-eight studies (72%) used prospective cohort de-
signs, 15 (19%) retrospective cohort designs and eight
(10%) cross-sectional designs (Additional file 4: Table
S4). The most common setting of medical care was
general hospitals or internal medicine settings in 29
studies (36%). Fourteen (17%) studies involved pa-
tients subject to highly specialised care (seven of
which included patients in surgery [33–39] and two
involving psychiatric patients [40, 41]), twelve (15%)
studies were situated in an emergency department, six
(10%) in an ICU and four (5%) studies in primary
care. The focus in nine (11%) of the studies was on
paediatric care units, with three of these studies being
situated in neonatal intensive care units [42–44].
Seven (9%) studies involved elderly patient care units,
six of which were specialised care units for geriatric
patients aged above 65 years [35, 45–49].
Preventable medication harm was assessed in 54 (67%)
studies by use of medical record reviews or observations.
In contrast, 27 (33%) studies reported preventable harm
by survey, telephone or spontaneous reporting surveil-
lance systems. At least one of the standard methods [28,
29] for assessing the preventability of medication harm
involving consensus between two or more trained re-
viewers (physicians or nurses) was applied in 48 (59%)
studies. However, 20 (25%) of the studies used adapted
scales where consensus procedures were not well known,
and 13 studies (16%) had not defined the method used
for assessment of preventability.
Fig. 1 PRISMA flowchart of the included studies
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Quality assessment
The median Newcastle-Ottawa score for included stud-
ies was 7 (range 6 to 9). Thirty-five studies (43%) scored
eight or above and were considered to be at low risk of
bias (see full assessment in Additional file 5: Table S5).
Pooled prevalence rates of medication-related harm
Table 1 shows that the unadjusted pooled prevalence of
preventable medication harm was 3% (95% CI 2 to 4%,
I2 = 99%) and the pooled prevalence of all medication
harm (inclusive of non-preventable) was 9% (95% CI 7
to 11%, I2 = 99.5%).
The highest prevalence rates for preventable medica-
tion harm were observed in elderly patient care units
(11%, 95% CI 7 to 15%, n = 7)), and patients in ICUs
(7%, 4 to 12%, n = 6)), highly specialised or surgical care
(6%, 3 to 11%, n = 13)) and emergency departments (5%,
2 to 12%, n = 12)) (Fig. 2). In contrast, the lowest preva-
lence rates were observed in paediatric care units (1%, 0
to 2%, n = 9), primary care (1%, 1 to 2%, n = 4) and gen-
eral hospitals or internal medicine settings (2%, 1 to 2%,
n = 29). Prevalence rates by patient age group are
provided in Fig. 3. These results re-enforce earlier find-
ings, showing greater preventable medication harms in
elderly patients (4%, 2 to 8%, n = 16) and the lowest rate
of preventable medication harm in paediatric patients
(1%, 0 to 2%, n = 9).
Clinical severity, stage of medication use and medication
group
As shown in Table 1, the proportions of clinical severity
for mild preventable medication harm was 39% (95% CI
28 to 51%, n = 20, I2 = 96.4%), moderate preventable
harm was 40% (31 to 49%, n = 22, I2 = 93.6%) and severe
or potentially life-threatening preventable harm was 26%
(15 to 37%, n = 28, I2 = 97%).
The highest rates of preventable medication harm
were sourced at the prescribing (58%, 95% 42 to 73%,
n = 9, I2 = 94%) and monitoring (47%, 95% 21 to 73%,
n = 8, I2 = 99%) stages. The stages with the lowest rates
of preventable medication harm were sourced at dis-
pensing (2%, 95% 0 to 6%, n = 6, I2 = 47%) and transcrib-
ing/documenting (3%, 95% 0 to 9%, n = 8, I2 = 78%)
stages.
Table 1 Proportions of the different types of preventable medication harm and overall medication harm















29 2 (1, 2) 98.4 1.6 (1.2–2.2) 5 (4, 7) 99.0 5.1 (3.2–10.9)
- Emergency department 12 5 (2, 12) 99.7 5.2 (2.1–12) 9.3 (4, 21) 99.8 6.2 (6.0–14)
- ICU 6 7 (4, 12) 91.1 6.8 (3.9–11.6) 14 (8, 23) 95.6 16.4 (9.5–20.2)
- Highly specialised
care or surgical
13 6 (3, 11) 98.7 5.4 (3.0–9.7) 18 (11, 26) 99.3 22.9 (17.8–26.2)
- Paediatric 9 1 (0, 2) 94.9 1.1 (0.1–2.1) 5 (2, 10) 99.2 5 (2.4–14.3)
- Elderly 7 11 (7, 15) 95.9 10.7 (7.2–15.4) 23 (13, 37) 99.1 24.8 (16–31.3)
- Primary care 4 1 (1, 2) 84.9 1.2 (1–1.9) 10 (6, 16) 99.0 9.9 (8–13.9)
- Psychiatric 1 1 (1, 2) NA NA 10 (9, 12) NA NA
Severity of preventable harm:
- Mild NA 39 (28, 51), n = 20 96.4 40 (21–49) 50 (44, 56), n = 47 98 46.9 (35.9–63.1)
- Moderate NA 40 (31, 49), n = 22 93.6 36.5 (28.1–54.4) 41 (36, 47), n = 54 98 37.3 (24.7–53.3)
- Severe/life-threatening NA 26 (15, 37), n = 28 97 19.5 (8–40) 14 (10, 19), n = 55 98 10 (6.4–18.6)
Stages of medication useβ:
1. Prescribing 9 58 (42, 73), n = 9 94 55.8 (35.4–77.3) 64 (34, 84), n = 18 98.5 52 (36–79)
2. Transcribing/documenting 8 3 (0, 9), n = 8 78 0.9 (0–6.3) 6 (1, 14), n = 17 89 2 (0.5–9)
3. Dispensing 6 2 (0, 6), n = 6 47 3.8 (0.9–4.1) 8 (2, 24), n = 15 69% 5.6 (1.3–8)
4. Administering 15 21 (11, 33), n = 15 93 20.8 (8.8–31.1) 25 (12, 40), n = 32 96.8 19 (7.6–30)
5. Monitoring 8 47 (21, 73), n = 8 99 54.9 (25.3–76) 54 (16, 82), n = 15 100 35 (15–70)
*Freeman-Tukey double arcsine transformation was used for the prevalence rate calculations
βStages of medication use follow the using the USA’s Pharmacopeia 5 major steps




Heterogeneity: I2 = 99%, τ2 = 1.5780, p = 0
Residual heterogeneity: I2 = 99%, p = 0
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Heterogeneity: I2 = 100%, τ2 = 2.7161, p = 0
Heterogeneity: I2 = 99%, τ2 = 1.3090, p < 0.01
Heterogeneity: I2 = 98%, τ2 = 0.8161, p = 0
Heterogeneity: I2 = 91%, τ2 = 0.4810, p < 0.01
Heterogeneity: I2 = 96%, τ2 = 0.3027, p < 0.01
Heterogeneity: I2 = 95%, τ2 = 0.9068, p < 0.01
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Fig. 2 Prevelance rates for preventable medication harm by healthcare system
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Preventable harm was greatest in medicines affecting
the ‘central nervous system’ (ATC code N) (21%, 95% 6
to 43%, n = 6) (see Table 2). However, prevalence rates
were also high in the ATC medication groups for ‘car-
diovascular’ (code C) (16%, 95% 11 to 23%, n = 14), ‘hyp-
notics and sedatives’ (code N05C) (16%, 95% 11 to 21%,
n = 5), ‘anti-inflammatory and antirheumatic products’
(code M01) (15%, 95% 7 to 26%, n = 5) and ‘antibiotics
and antibacterial for systemic use’ (code J01) (12%, 95%
7 to 18%, n = 12). The prevalence rate was below 5% for
patients receiving ‘respiratory system-related drugs’
(code R), drugs for patients with ‘functional gastrointes-
tinal disorders’ (code A03), patients taking ‘corticoste-
roids for systemic use’ (code H02) and ‘antiepileptics’
(code N03). The top five medication groups associated
with preventable medication harm in each of the 20
studies is provided in Additional file 6: Table. S6.
Meta-regressions to explore heterogeneity in the
prevalence of preventable medication harm
Table 3 shows the results of the univariable and multi-
variable analysis. The univariable analyses showed that
the prevalence of preventable medication harm was
higher across studies with smaller (≤ 1200 patients) sam-
ple sizes (b = 0.111, 95% confidence interval 0.064 to
0.159), those carried out in Europe (b = 0.031, − 0.0002
to 0.061) and at lower risk of bias (b = 0.075, 0.022 to
0.128). The prevalence of preventable harm was lower in
children or adolescent-based studies (b = − 0.088, − 0.151
to − 0.025) and in studies that assessed medication harm
by survey, telephone or spontaneous reporting surveil-
lance systems (b = − 0.026, − 0.053 to 0.0003). When
compared to general hospitals/internal medicine, health-
care settings involving the elderly (b = 0.094, 0.052 to
0.136), emergency departments (b = 0.042, 0.011 to
0.073), highly specialised or surgical care (b = 0.062,
0.030 to 0.093) or intensive care (b = 0.052, 0.010 to
0.094) showed elevated significant levels of preventable
harm. These five variables (sample size, healthcare set-
ting, WHO region, age group, assessment method and
low risk of bias) were therefore eligible for inclusion in
the multivariable regression analysis.
The multivariable model was statistically significant (χ2
(6) = 44.228, P < 0.001, R2 = 37.65%) and reduced the I2
statistic from 99 to 61.3%. Only two of the variables
remained statistically significant; studies with low sample
sizes (b = 0.038, 0.016 to 0.060) and the three healthcare
setting groups, including elderly patient care (b = 0.07,
0.023 to 0.107), emergency medicine (b = 0.028, − 0.002
to 0.058) and highly specialised care (b = 0.052, 0.022 to
0.082), were all associated with a higher prevalence of
preventable medication harm.
Publication bias
Additional file 7: Fig. S1 shows some evidence of publica-
tion bias as indicated by visual inspections of the funnel
plots and by the Egger regression test for small study ef-
fects for the primary outcome (bias coefficient for the
main analysis 1.39, 95% 0.38 to 3.47, P < 0.001). Trim-
and-fill method also revealed evidence of publication bias.
Fig. 3 Prevelance rates for preventable medication harm by
age group
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Discussion
This meta-analysis found that preventable medication
harm occurs in 3% of patients across medical care set-
tings and that at least a quarter of preventable medica-
tion harm is severe or potentially life threatening. In our
previous meta-analysis, the prevalence of preventable pa-
tient harm (e.g. adverse events due to any type medical
errors—not only medication) was 6%, and only one tenth
of this harm was severe or potentially life-threatening
[50]. Thus, medication harm indeed accounts for half of
the overall preventable harm in medical care. The
present findings also align closely to a recent narrative
meta-review of systematic reviews [51], which looked at
the preventability of ADRs in patients receiving acute or
ambulatory care—reporting a prevalence rate of 3.13%.
However, this earlier narrative overview involved only 37
studies compared to the 81 studies in our meta-analysis,
did not include patients in primary care or emergency
care settings and did not examine thoroughly the sever-
ity of harm, patient age, stage of medication use and
high-risk medication groups.
The highest prevalence rate of preventable medica-
tion harm was seen in studies based on elderly care
units which often involve patients with high comor-
bidity and hence polypharmacy. The headline policy
implication of this study therefore is that mitigation
strategies for preventable medication harm are pri-
marily needed for older people with multimorbidity/
polypharmacy—which is indeed a key priority area of
the WHO safety initiative [16, 52]. A recent review
that tried to determine which interventions, alone or
in combination, were effective in improving the ap-
propriate use of polypharmacy and reducing medica-
tion related harms in older people [53], revealed great
uncertainty about the effectiveness of comprehensive
medicines reviews of patient prescriptions and urged
for further research. Since the last update of this re-
view, a Scottish working group has published a guid-
ance document on polypharmacy, which included a
seven-step process for standardised and structured
medicines reviews that are holistic, patient-centred
and consider non-pharmacological treatments [54], as
well as a review of the quality of development of
available guidelines to promote appropriate polyphar-
macy [55]. Further population-based research is
needed to evaluate the implementation and effect of
these resources on prescribing for older people.
Moreover, medication harm in ICUs [56] and acute
specialised care settings involving surgery [57] was asso-
ciate with higher volumes of preventable medication
harm and should, therefore, also be considered as high-
risk patient care settings. Evidence concerning the preva-
lence and severity of preventable medication harm in
primary care and psychiatry was scarce. We only found
four studies based in primary care, where over 80% of
healthcare services are delivered internationally [58], and
only one study was identified in psychiatry. It is there-
fore possible that certain types of preventable harm in
Table 2 Proportions of preventable medication harm by medication class
Drug class ATC code N studies Prevalence, % 95% CI τ2 I2 (%)
Analgesics N02¥ 4 7 0.5, 19 0.0229 84.00
Antibiotics and antibacterial J01¥ 12 12 7, 18 0.0165 87.80
Antithrombotic agents/anticoagulants B01¥ 10 11 7, 15 0.0073 78.60
Antidepressants N06Aβ 4 6 0.4, 17 0.0253 94.90
Antidiabetic A10¥ 4 7 0.8, 17 0.0162 77.50
Antiepileptics N03¥ 3 4 0.2, 10 0.0029 26.40
Anti-inflammatory and antirheumatic M01¥ 5 15 7, 26 0.0166 79.40
Antipsychotics N05Aβ 4 11 0.2, 32 0.0622 95.60
Cardiovascular C* 14 16 11, 23 0.0205 90.80
Corticosteroids H02¥ 5 2 0.2, 6 0.0066 77.10
Diuretics C03¥ 5 6 0.2, 17 0.0365 95.80
Functional gastrointestinal disorders A03¥ 3 4 0, 14 0.0183 75.80
Musculoskeletal system M* 3 9 2.4, 20 0.0142 85.00
Nervous system N* 6 21 6, 43 0.0784 97.00
Opioids N02Aβ 5 6 2, 10 0.0045 74.70
Respiratory system-related drugs R* 4 1 0, 4 0.0061 74.90
Sedatives N05Cβ 5 16 11, 21 0.0016 33.50
*ATC 1st level—related to mostly body function;
¥ATC 2nd level—pharmacological or therapeutic subgroup
βATC 3rd and 4th levels—chemical, pharmacological or therapeutic subgroup
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Table 3 Univariable and multivariable meta-regression analysis of prevalence estimation for preventable medication harm
Univariable Multivariable
Variable No. Regression coefficient
(95% CI)




- Asia/other 32 1 – – 1 – –
- North America 23 0.018 (−0.014, 0.049) 0.016 0.273 0.03 (−0.02, 0.087) 0.028 0.237
- Europe 26 0.031 (− 0.0002, 0.061) 0.016 0.051 0.011 (− 0.045, 0.066) 0.028 0.709
Drug classification:
- Yes 67 1 – – – – –
- No 14 − 0.011 (− 0.081, 0.059) 0.036 0.760 NA NA NA
Sample size*:
- > 1,200 patients 41 1 – – 1 – –
- ≤ 1,200 patients 40 0.111 (0.064, 0.159) 0.024 < 0.0001 0.038 (0.016, 0.060) 0.011 0.036
Age group:
- Adults 63 1 – – 1 – –
- Children/adolescents 18 − 0.088 (− 0.151, − 0.025) 0.032 0.0060 − 0.016 (− 0.048, 0.016) 0.016 0.319
Healthcare setting:
- General hospital or internal medicine 29 1 – – 1 – –
- Elderly 7 0.094 (0.052, 0.136) 0.021 < 0.0001 0.07 (0.023, 0.107) 0.021 0.002
- Emergency department 12 0.042 (0.011, 0.073) 0.016 0.009 0.028 (− 0.002, 0.058) 0.015 0.062
- Highly specialised care or surgical 13 0.062 (0.030, 0.093) 0.016 0.0001 0.052 (0.022, 0.082) 0.015 0.0007
- ICU 6 0.052 (0.010, 0.094) 0.021 0.015 0.038 (− 0.004, 0.080) 0.021 0.073
- Paediatric 9 − 0.008 (− 0.044, 0.028) 0.018 0.663 − 0.0001 (− 0.044, 0.043) 0.022 0.996
- Primary care 4 − 0.009 (− 0.056, 0.039) 0.024 0.720 − 0.014 (− 0.058, 0.031) 0.023 0.547
- Psychiatric 1 − 0.010 (− 0.100, 0.080) 0.046 0.825 − 0.006 (− 0.090, 0.079) 0.043 0.897
Assessment method:
- Medical record review/chart review
or observation
54 1 – – 1 – –
- Survey, telephone, voluntary
(spontaneous) report
27 − 0.026 (− 0.053, 0.0003) 0.014 0.053 − 0.021 (− 0.045, 0.004) 0.012 0.099
Standard method for preventability:
- Yes 49 1 – – NA NA NA
- No 32 − 0.014 (− 0.069, 0.040) 0.028 0.613 NA NA NA
Length of study:
- ≤ 6 months 47 1 – – NA NA NA
- > 6 months 34 −0.026 (−0.080, 0.029) 0.028 0.357 NA NA NA
Design:
- Prospective 58 1 – – – – –
- Retrospective cohort or cross-sectional 23 0.011 (− 0.019, 0.040) 0.015 0.480 NA NA NA
Risk of bias:
- High (score < 7) 31 1 – – NA NA NA
- Low (score ≥ 7) 50 0.075 (0.022, 0.128) 0.027 0.006 0.019 (− 0.004, 0.043) 0.012 0.107
Model fit indices χ2 (6) = 44.228, P < 0.001, R2 = 37.65%
SE standard error, NA not applicable
*Medium number of patients = 1200
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psychiatry settings may remain undetected, as these
harms often result from multiple interacting errors from
violation provoking conditions and latent ‘system’ fail-
ures [22, 59]. Thus, there is a need for more research in
both these care settings.
The prescribing and monitoring stages of medication
use were key sources of preventable harm. The adoption
of electronic health records and electronic prescribing
has helped avert preventable harm at the prescribing
and transcribing stages [14, 60–66], but preventable
harm persists across all pathways of medication use.
This is most likely due to underlying system flaws that
allow individual errors such as those in prescribing or
medicines administration to reach the patient and cause
serious harm [67]. Human factors play an important role
in understanding these system flaws; for instance, there
may be a lack of standard procedures for storage of
medications that look alike, poor communication be-
tween different providers, lack of verification before
medication administration and limited involvement of
patients in their own care [68–71]. Better safeguarding
processes that acknowledge the contribution of human
factors and systems thinking are required at the different
points of medication use to ensure correct measures are
contributing to healthcare improvement efforts [72].
We found that medication groups that gave rise to
most preventable medication harm include; central ner-
vous system, cardiovascular, hypnotics and sedatives,
anti-inflammatory and antirheumatic, antibiotics and
antibacterial drugs. Many of these medication groups
have been previously assessed in relation to hazardous
prescribing in the past [14, 15]. However, the interven-
tions featured in these studies deliberately focused on
potential medication errors rather than preventable
harm, and therefore, available evidence has not yet de-
termined whether these interventions will reduce harm
to patients. This stresses further the urgency and need
to focus on assessment of medication errors and harm
in conjunction [13, 71], as well as new ways of reducing
medication harms in older people [53].
Most efforts so far originate in developed countries
[73], and so the rate of preventable medication harm
from less developed countries remains relatively un-
known. However, in one study, the preventability of ad-
verse events across 26 hospitals in eight low-and middle-
income countries showed an adverse event rate to be
around 8%. Of these events, 83% were preventable, while
about 30% were associated with death of the patient
[74]. Although this is likely to be an underestimate with
higher rates of excess death unaccounted for, it shows
that patient safety is a much bigger problem in these de-
veloping and transitional countries, when judged by the
preventability and severity of harm (number of prevent-
able deaths). These results are somewhat contrasting
with our results, with the higher rate of preventable
harm being found in studies from Europe. However,
these findings might reflect the limitations that exist in
assessing preventable medication harm in developing
countries. Moreover, the prevention of medication harm
is often complex and involves improving basic clinical
processes and does not simply depend on the provision
of more resources [75].
Despite this being the first large meta-analysis to as-
sess the prevalence of preventable medication harm
across healthcare settings, there still remain several limi-
tations. First, a considerable proportion of the high het-
erogeneity remained unexplained in meta-regressions.
Several other factors such as differences in systems, pro-
cedures and variations in timeframe used to evaluate
medication harm remain largely unknown and may be
responsible for this unexplained heterogeneity.
Second, whilst we performed exhaustive searches for
unpublished studies, the exclusion of non-English writ-
ten studies and the presence of publication bias that
forms of selection bias or system bias is likely [76]. We
tried to account for this in the analysis by adjusting for
sample size, but some of the causal factors remain
unexplained.
Third, studies not reporting data on preventable medi-
cation harm were excluded from the analyses. Among
the included studies, only 36% of studies provided an
analysis of severity and even the classification system
used was unclear at times so a pragmatic judgement was
made to group some of the severity categories. Further-
more, discussions of causality assessment were limited
with few studies reporting the exact assessment tool
used, and only 22% of studies provided the stage of
medication use, and whilst harm was reported by medi-
cation group in 78% of the studies, only one fifth of
these provided data at the preventable level. The use of
different preventability scales may also incur a level of
‘hindsight bias’, where healthcare professionals may be
subject to overestimation of their ability to predict pre-
ventable harm events [77, 78]. However, adjustment for
this in observation research can be a significant chal-
lenge in evidence synthesis.
Finally, more than two thirds of preventable medica-
tion harm were examined retrospectively through med-
ical case notes and chart reviews. Although case note
reviews are the most universally used method for asses-
sing medication harm to date, patients and healthcare
providers suggest that case reviews still lack the robust-
ness to detect diagnostic error and are susceptible to
time-delay issues in the absence of regular patient con-
sultation [79]. Combining methods that prospectively
uncover preventable harm by use of the ‘failure mode
and effect analysis’, ‘structured what-if technique’ [13],
pharmacist screening, or patient surveys along with
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retrospective error detection methods including trigger
tools, voluntary reporting systems, root cause analysis or
mortality reviews [76, 80] would provide better and
more promising approaches for enhancing the detection
of preventable medication harm.
Conclusions
Our study findings confirm that preventable medication-
related harm is a frequent and enduring serious prob-
lem, causing severe or potentially life-threatening out-
comes in over a quarter of all preventable harm cases. A
highly problematic healthcare setting was in geriatric
care, specialised care settings, intensive care or those in
emergency departments. Elderly patients are at greater
risk of polypharmacy, and patients in other specialised
or emergency medicine settings may be exposed to
higher-risk mediation groups. As both are priority areas
of the WHO’s safety initiative, we have gone some way
in this review to providing a basis of evidence to support
future policy developments in this area. Nevertheless,
further research is needed in primary care and psych-
iatry settings where up to 80% of healthcare service is
delivered, alongside efforts to better understand where
improvements can be made in less-developed countries.
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